Endothelin signaling in diabetic kidney disease: therapeutic targeting and translational advances
- 1Department of Nephrology, Ansteel General Hospital
- 2Department of Cardiac Surgery, Ansteel General Hospital
Abstract
Diabetic kidney disease (DKD) is the most prevalent microvascular complication of type 2 diabetes mellitus (T2DM) and a leading global cause of end-stage kidney disease (ESKD). Current first-line regimens, including renin-angiotensin-aldosterone system inhibitors and sodium-glucose cotransporter 2 inhibitors, only partially slow the decline in renal function, and a substantial proportion of patients retain residual renal risk. Endothelin-1 (ET-1), a vasoactive peptide produced by intrinsic renal cells, drives the progression of DKD through endothelin A receptor (ETAR)-mediated hemodynamic, podocyte, mesangial, and tubulointerstitial injury, whereas protective endothelin B receptor signaling is impaired. Selective ETAR antagonists reduce albuminuria and kidney events in clinical trials, but fluid retention and heart failure signals limit their routine use, and combination strategies are under evaluation in ongoing phase III trials. ET-1 also serves as a candidate non-invasive biomarker for early DKD detection and prognosis. This narrative review integrates the molecular mechanisms of endothelin system activation, the multilayered renal injury mediated by the ET-1/ETAR axis, the clinical evidence for endothelin receptor antagonists, and the biomarker value of ET-1. We further discuss the potential interface between the gut-kidney axis and the endothelin system, and we outline the research priorities that could translate this pathway into precision therapy for DKD.
Related
- Targeting the NLRP3 inflammasome in rheumatoid arthritis fibroblast-like synoviocytes: pathogenic mechanisms, therapeutic strategies, and translational perspectives
- Post-Translational Modification Crosstalk in Gastric Cancer: Molecular Switches, Signaling Networks, and Therapeutic Opportunities, with Comparative Insights from Colorectal Cancer
- Advanced cell-laden hydrogels for diabetic wound healing: Biomaterial design, therapeutic mechanisms, and translational challenges
- Beyond Thr172 phosphorylation: subunit-selective, spatial, and post-translational AMPK signaling in diabetic cardiomyopathy
- Targeting CD300a Signaling With a Phosphatidylserine‐Presenting Hydrogel Rescues Macrophage Dysfunction and Accelerates Diabetic Wound Healing
BibTeX
@article{ma2026endothelin,
title = {{Endothelin signaling in diabetic kidney disease: therapeutic targeting and translational advances}},
author = {Li Ma and Wenhua Liu and Xiaotong Wang and Dan Liu and Honghan Liu},
journal = {Frontiers in Endocrinology},
year = {2026},
month = nov,
doi = {10.3389/fendo.2026.1942018},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1942018/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Endothelin signaling in diabetic kidney disease: therapeutic targeting and translational advances
AU - Li Ma
AU - Wenhua Liu
AU - Xiaotong Wang
AU - Dan Liu
AU - Honghan Liu
PY - 2026
DA - 2026/11/02
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1942018
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1942018/full
AB - Diabetic kidney disease (DKD) is the most prevalent microvascular complication of type 2 diabetes mellitus (T2DM) and a leading global cause of end-stage kidney disease (ESKD). Current first-line regimens, including renin-angiotensin-aldosterone system inhibitors and sodium-glucose cotransporter 2 inhibitors, only partially slow the decline in renal function, and a substantial proportion of patients retain residual renal risk. Endothelin-1 (ET-1), a vasoactive peptide produced by intrinsic renal cells, drives the progression of DKD through endothelin A receptor (ETAR)-mediated hemodynamic, podocyte, mesangial, and tubulointerstitial injury, whereas protective endothelin B receptor signaling is impaired. Selective ETAR antagonists reduce albuminuria and kidney events in clinical trials, but fluid retention and heart failure signals limit their routine use, and combination strategies are under evaluation in ongoing phase III trials. ET-1 also serves as a candidate non-invasive biomarker for early DKD detection and prognosis. This narrative review integrates the molecular mechanisms of endothelin system activation, the multilayered renal injury mediated by the ET-1/ETAR axis, the clinical evidence for endothelin receptor antagonists, and the biomarker value of ET-1. We further discuss the potential interface between the gut-kidney axis and the endothelin system, and we outline the research priorities that could translate this pathway into precision therapy for DKD.
SN - 1664-2392
ER -